Across TCGA pan-cancer cohorts, KLHL22 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of KLHL22’s most consistent transcriptional readouts.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where KLHL22 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types KLHL22 is over-expressed in tumor, although a few such as CCRCC and LUAD show the opposite, repressed pattern.
CCRCC, LUAD, and LSCC are the cancer types where KLHL22 tumor–normal differential expression is most reproducible.